Statins and cognitive decline in patients with Alzheimer’s and mixed dementia: a longitudinal registry-based cohort study.
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
Background: Disturbances in brain cholesterol homeostasis may be involved in the pathogenesis of Alzheimer’s disease (AD). Lipid-lowering medications could interfere with neurodegenerative processes in AD through cholesterol metabolism or other mechanisms. Objective: To explore the association between the use of lipid-lowering medications and cognitive decline over time in a cohort of patients with AD or mixed dementia with indication for lipid-lowering treatment. Methods: A longitudinal cohort study using the Swedish Registry for Cognitive/Dementia Disorders, linked with other Swedish national registries. Cognitive trajectories evaluated with mini-mental state examination (MMSE) were compared between statin users and non-users, individual statin users, groups of statins and non-statin lipid-lowering medications using mixed-effect regression models with inverse probability of drop out weighting. A dose-response analysis included statin users compared to non-users. Results: Our cohort consisted of 15,586 patients with mean age of 79.5 years at diagnosis and a majority of women (59.2 %). A dose-response effect was demonstrated: taking one defined daily dose of statins on average was associated with 0.63 more MMSE points after 3 years compared to no use of statins (95% CI: 0.33;0.94). Simvastatin users showed 1.01 more MMSE points (95% CI: 0.06;1.97) after 3 years compared to atorvastatin users. Younger (< 79.5 years at index date) simvastatin users had 0.80 more MMSE points compared to younger atorvastatin users (95% CI: 0.05;1.55) after 3 years. Simvastatin users had 1.03 more MMSE points (95% CI: 0.26;1.80) compared to rosuvastatin users after 3 years. No differences regarding statin lipophilicity were observed. The results of sensitivity analysis restricted to incident users were not consistent. Conclusions: Some patients with AD or mixed dementia with indication for lipid-lowering medication may benefit cognitively from statin treatment; however, further research is needed to clarify the findings of sensitivity analyses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992 · cited 1×
“Clinical trials generally reported a null effect [34–36] but were commonly underpowered or used less robust cognitive evaluation tools.”
BackgroundNeurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
New insights into the genetic etiology of Alzheimer’s disease and related dementias
Bellenguez, C., Küçükali, F., Jansen, I. E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01024-z · Cited by 2,498
Wettermark, B., Hammar, N., MichaelFored, C., Leimanis, A., Otterblad Olausson, P., Bergman, U., Persson, I., Sundström, A., Westerholm, B., & Rosén, M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1294 · Cited by 1,887
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
Schachter, M. (2005) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00299.x · Cited by 1,211
Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons
Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C. G., & Simons, K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6460 · Cited by 1,166
Brain Cholesterol: Long Secret Life Behind a Barrier
Björkhem, I., & Meaney, S. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000120374.59826.1b · Cited by 1,044 · cited 1×
“The brain houses about a quarter of the cholesterol pre-sent in the body, making it the richest cholesterol-containing organ [1].”
BackgroundPleiotropic Effects of Statins - Basic Research and Clinical Perspectives -
Zhou, Q., & Liao, J. K. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0110 · Cited by 567
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
The Clinical Problem of Symptomatic Alzheimer Disease and Mild Cognitive Impairment
Tarawneh, R., & Holtzman, D. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006148 · Cited by 471
Cited by
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
Kim, A. Y., Jerdi, S. A., MacDonald, R., & Triggle, C. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399121 · Cited by 116
A 2025 update on treatment strategies for the Alzheimer’s disease spectrum
Wu, C.-K., & Fuh, J.-L. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001252 · Cited by 77
“55 Managing vascular risk factors, such as hypertension, diabetes, and hyperlipidemia, is essential for slowing disease progression.”
Alzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective
Scarano, N., Musumeci, F., Casini, B., Brullo, C., D’Ursi, P., Fossa, P., Schenone, S., & Cichero, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146980 · Cited by 37
The pathophysiology of mixed Alzheimer's disease and vascular dementia
Sarhan, M., Wohlfeld, C., Perry-Mills, A., Meyers, J., Fadel, J., Murphy, E. A., Bonilha, L., & Fan, D. (2025) · Theranostics · doi:10.7150/thno.118737 · Cited by 31
Bioenergetics and lipid metabolism in Alzheimer's disease: From cell biology to systemic health
Maioli, S., Nalvarte, I., Ankarcrona, M., Schultzberg, M., Zuloaga, K. L., Goikolea, J., Visser, P. J., Strooper, B. D., Winblad, B., Pizzo, P., et al. (2025) · Journal of Internal Medicine · doi:10.1111/joim.70036 · Cited by 21
Self-citation
Metadata
- Authors
- Petek, B., Häbel, H., Xu, H., Villa-Lopez, M., Kalar, I., Hoang, M. T., Maioli, S., Pereira, J. B., Mostafaei, S., Winblad, B., Gregoric Kramberger, M., Eriksdotter, M., & Garcia-Ptacek, S.
- Affiliations
- University of Ljubljana (SI)
- Karolinska Institutet (SE)
- Karolinska University Hospital (SE)
- Corresponding author
- Petek, Bojana
- ORCID
- Venue
- Alzheimer's Research & Therapy
- Published
- 2023-12-20
- Volume
- 15
- Issue
- 1
- Pages
- 220-220
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC10731754
- OpenAlex
- W4389966265
- Cited by
- 65
- References
- 72
- Citations by year
- 2026: 18 · 2025: 34 · 2024: 13
- FWCI
- 13.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Stiftelsen Dementia
- Margaretha af Ugglas Foundation
- Health, Medicine and Technique grants from the Stockholm Region and Kungliga Tekniska Högskolan
- Johanniterorden i Sverige/Swedish Order of St John
- Medicinska Forskningsrådet (2020-02014, 2022-01425)
- Karolinska Institutet Research Foundation
- Karolinska Institutet Foundation for Diseases of Aging
- The Erling Persson foundation
- New Innovative Research grants
- Innovative ways to fight Alzheimer´s disease - Leif Lundblad Family and others
- Karolinska Institute
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- statins, cognitive decline, Alzheimer's disease, mixed dementia, lipid-lowering drugs, cholesterol homeostasis, simvastatin, atorvastatin, rosuvastatin, dose-response relationship, brain cholesterol metabolism, cognitive trajectories
- MeSH terms
- Atorvastatin, Mixed Dementias, Aged, Alzheimer Disease, Cholesterol, Female, Humans, Longitudinal Studies, Cohort Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statins and cognitive decline in patients with Alzheimer’s and mixed dementia: a longitudinal registry-based cohort study. https://app.cochat.ai/papers/10.1186/s13195-023-01360-0
- The paper
- Petek, B., Häbel, H., Xu, H., Villa-Lopez, M., Kalar, I., Hoang, M. T., Maioli, S., Pereira, J. B., Mostafaei, S., Winblad, B., Gregoric Kramberger, M., Eriksdotter, M., & Garcia-Ptacek, S. (2023). Statins and cognitive decline in patients with Alzheimer’s and mixed dementia: a longitudinal registry-based cohort study. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-023-01360-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.